Research programme: Nanobodies - Ablynx

Drug Profile

Research programme: Nanobodies - Ablynx

Alternative Names: ABX-0401; ABX-0402; ABX-0403; ALX-0962 (anti-IgE antibody); Anti-IgE Nanobody; Anti-TNF Nanobodies; Anti-VWF Nanobody

Latest Information Update: 22 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Class Proteins
  • Mechanism of Action IgE receptor antagonists; Immunomodulators; Interleukin 6 receptor modulators; RANK ligand inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Allergic asthma; Autoimmune disorders; Bone disorders; Cancer; Infections; Inflammation; Respiratory syncytial virus infections; Respiratory tract disorders; Thrombotic thrombocytopenic purpura

Most Recent Events

  • 19 Jun 2018 Ablynx has been acquired by Sanofi
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in Belgium (Parenteral, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Belgium (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top